Acquisition of Exclusive Pharmaceuticals from DLA Farmacêutica - Glycerol 3830 – 2026 (2)

This tender is for the acquisition of specific exclusive pharmaceuticals, namely 'Glycerol 3830', sourced from 'DLA Farmacêutica'. The procurement is designated for the year 2026, with the '(2)' possibly indicating a second call or a specific batch within that year. Glycerol is a chemical compound with various applications, including pharmaceutical uses as a solvent, humectant, or sweetener in medications and medical preparations. The term 'exclusive' suggests that this particular product or formulation might be sourced solely through DLA Farmacêutica or under specific contractual terms. The contracting authority, likely a healthcare provider or pharmaceutical distributor, is seeking to secure a supply of this specific medication. The tender documents will detail the required quantities, quality standards (e.g., pharmacopeia compliance), packaging, delivery schedules, and any specific regulatory requirements for the supply of this pharmaceutical product for the year 2026.

This is a supplies contract in the health and medical services, trade and industry and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 4,093.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.